[Affection of central nervous system in hemorrhagic fever with renal syndrome].

The authors report results of comparative analysis of 897 cases of hemorrhagic fever with renal syndrome diagnosed in the Upper Amur region in 1960-2005. All the patients were grouped by 5-year intervals depending on the severity of clinical condition. The frequency of CNS affection accompanied by acute psychic disorders, convulsive and meningeal syndromes varied significantly in different years. Pituitary hemorrhage was revealed at autopsy in 36.8% of the patients, pituitary necrosis in 5.2%, brainstem hemorrhage in 68.4%. A case of severe hemorrhagic fever with renal syndrome is described characterized by acute renal insufficiency and eclamptic convulsions with moderately manifest hemorrhagic syndrome preceding the favourable outcome.

[Observations on clinic curative effect of oxymatrine to cure hemorrhagic fever with renal syndrome (HFRS)].

OBJECTIVE: To observe the curative effect of oxymatrine to cure hemorrhagic fever with renal syndrome. METHODS: Randomly divide 418 patients suffering from hemorrhagic fever with renal syndrome into a treatment group and a control group, use oxymatrine to give an intravenous drip to the patients in the treatment group, one time a day, each time 600 mg, lasting for 7 days as one period of treatment and meanwhile take a traditional equilibrium salt treatment for the patients in the control group. Observe the change of the illness in both groups and occurrence of complications, dynamically test the magnitude of serum urination-regulated protein (THP) and beta(2) microglobulin (beta(2)M) of the patients, in the meantime observe the change in magnitude of serum white blood cell medium 15 (IL-15) and soluble intercellular adhesion molecules (sICAM-1). RESULTS: Shorten the course of the disease of the patients in the oxymatrine treatment group, make an improvement after the recovery and obviously reduce the magnitude of serum urination-regulated protein (THP) and beta(2) microglobulin and show a striking difference in magnitude of serum IL-15 and sICAM-1 after the treatment compared with that of the patients in the control group. CONCLUSION: Oxymatrine has a certainly true curative effect to hemorrhagic fever with renal syndrome and worth of furthering its widespread use in clinics.

Treating viral hemorrhagic fever.

Viral hemorrhagic fevers are illnesses associated with a number of geographically restricted, mostly tropical areas. Over recent decades a number of new hemorrhagic fever viruses have emerged. Advances in our understanding of the pathophysiology of these diseases have improved our initial supportive management and led to the recognition of several potentially useful antiviral agents. This review focuses on these hemorrhagic fever viruses and specifically addresses therapeutic aspects and recent progress that has been made in the treatment of these viral pathogens.

[Use of amixin in the therapy and prevention of some viral infections]. / Opyt primeneniia amiksina pri lechenii i profilaktike nekotorykh virusnykh infektsionnykh zabolevanii.

The trial of oral interferon inductor amixin for effectiveness in chronic viral hepatitis (CVH) and hemorrhagic fever with renal syndrome (HFRS) has shown that amixin in CVH improved general condition of the patients, removed yellowness of the skin and sclera, normalized activity of aminotransferases and blood bilirubin level. Virus replication was stopped in 25 and 1.6% in CVHB and CVGC, respectively. Amixin in HFRS was effective if received early. Preventive amixin therapy in population groups with high HFRS risk prevents development of HFRS and acute respiratory viral infection.

Reappearance of viral hemorrhagic fever with renal syndrome in northwestern Greece.

BACKGROUND: Minor outbreaks of viral hemorrhagic fever (VHF) with renal failure have occurred in northwestern Greece over past decades. However, during the most recent decade, there has been a paucity of human cases despite the detection of hantavirus in rodents of this area. CASE REPORTS: We present herein the cases of two patients with VHF, arising in the same area, hospitalized for a short period of time. One patient presented with renal failure, while severe hepatic involvement was predominant in the other. Significantly high ELISA antibody titers for hantavirus established the diagnosis. Supportive treatment led to a successful outcome in both cases. We further discuss the difficulties in differential diagnosis of VHF from other zoonoses with similar endemicity, such as leptospirosis. CONCLUSIONS: Awareness of the continuing presence of VHF in rural Greece is needed, and a rapid diagnosis is important for the correct therapeutic approach. Continuous surveillance for such diseases, at both the animal (rodents) and human level, is warranted.

[Observation on effect of chongcao shenkang capsules in preventing and treating acute renal failure in cases of hemorrhagic fever with renal syndrome].

OBJECTIVE: To observe the effect of Chongcao shenkang capsules in preventing and treating acute renal failure in cases of hemorrhagic fever with renal syndrome (HFRS). METHODS: 150 cases of HFRS were randomly divided into two groups: the treatment group and the control group. The former contained 76 cases and the latter the 74 cases. All cases in both groups were given a combined therapy mainly composed of balanced salt solution and ribavirin, cases in treatment group additionally accepted Chongcao shenkang capsules 2.7 grams tid, till the end of polyuric phase. RESULTS: The results showed that in the treatment group the occurrence rate of cases with oliguric phase was 13.0% (4/46) and the oliguric and polyuric periods were 2.7 +/- 1.6 days and 6.8 +/- 2.9 days respectively while those in the control group were 31.1% (4/45), 4.3 +/- 2.1 dnys and 8.2 +/- 3.4 days respectively (P < 0.01 or P < 0.05). The urinary protein of the treatment group disappeared within 5.1 +/- 2.3 days and their serum creatinine restored within 10.9 +/- 6.2 days, but the urinary protein disappearing and the serum creatinine restoring periods of the control group were 6.8 +/- 2.7 days and 13.7 +/- 7.4 days respectively (P < 0.01 or P < 0.05). The serum and urine beta 2-microglobulin levels of the treatment group were remarkably lower than those of the control group on the fifth and tenth days after treatment (P < 0.01 or P < 0.05). Compared with those of the control group of 33.8% (25/74) and 87.8% (65/74), the occurrence rate of severe complications and curative rate of the treatment group were 18.4% (14/76) and 94.7% (72/76) respectively (the former P < 0.05, but the latter P > 0.05). CONCLUSION: It was concluded that Chongcao shenkang capsules is capable of reducing the occurrence rate of acute renal failure in HFRS patients, shortening the duration of acute renal failure, decreasing their needs for dialysis, lessening their complications and increasing their curative rate. Its administration is safe and convenient and therefore it is worthy to be popularized.